» Articles » PMID: 2066971

2-[(arylmethyl) Amino]-2-methyl-1,3-propanediol DNA Intercalators. An Examination of the Effects of Aromatic Ring Variation on Antitumor Activity and DNA Binding

Overview
Journal J Med Chem
Specialty Chemistry
Date 1991 Jul 1
PMID 2066971
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of variation of aromatic ring size, shape, and side-chain position on antitumor activity and DNA binding in a series of carbocyclic 2-[(arylmethyl)amino]-2-methyl-1,3-propanediols (AMAPs) were examined. In general, the interaction of AMAPs with DNA increases as the intercalating ring system grows in area, with three distinct binding levels evident. Isomers from a specific ring system appear to bind DNA similarly. DNA binding is not the sole criterion for antitumor activity for the AMAPs studied; the magnitude of the delta Tm does not correlate with the antitumor activity observed. Significant in vivo P388 activity was seen for AMAP congeners from several tetracyclic ring systems. However, isomers from each of the specific ring systems produced a wide range of in vivo P388 activity. Thus, AMAP antitumor activity is not a function of the ring system per se, but rather appears to be related to the shape of the specific molecule. Three AMAP congeners (crisnatol (770U82, 773U82, and 502U83) are currently in clinical trials.

Citing Articles

Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.

Kokosza K, Andrei G, Schols D, Snoeck R, Piotrowska D Bioorg Med Chem. 2015; 23(13):3135-46.

PMID: 26001344 PMC: 7126999. DOI: 10.1016/j.bmc.2015.04.079.


Novel disubstituted chrysene as a potent agent against colon cancer.

Banik B, Basu M, Becker F Oncol Lett. 2012; 1(6):1033-1035.

PMID: 22870108 PMC: 3412534. DOI: 10.3892/ol.2010.167.


Polycyclic aromatic compounds as anticancer agents: Evaluation of synthesis and in vitro cytotoxicity.

Bandyopadhyay D, Granados J, Short J, Banik B Oncol Lett. 2012; 3(1):45-49.

PMID: 22740854 PMC: 3362437. DOI: 10.3892/ol.2011.436.


An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials.

Zucker R, Adams D, Bair K, Elstein K Invest New Drugs. 1992; 10(1):1-15.

PMID: 1607248 DOI: 10.1007/BF01275471.